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ABSTRACT 
 The HLA-DR15 haplotype confers the largest part of the genetic risk to 
develop multiple sclerosis, a prototypic CD4+ T cell-mediated autoimmune disease. 
The mechanisms how certain HLA-class II molecules functionally contribute to 
autoimmune diseases are still poorly understood, but probably involve shaping an 
autoimmune-prone T cell repertoire during central tolerance in the thymus and 
subsequently maintaining or even expanding it in the peripheral immune system. 
Self-peptides that are presented by disease-associated HLA-class II molecules most 
likely play important roles during both processes. Here, we examined the functional 
involvement of the HLA-DR15 haplotype in autologous proliferation in multiple 
sclerosis and the contribution of HLA-DR15 haplotype-derived self-peptides in an in 
vitro system. We observe increased autologous T cell proliferation in multiple 
sclerosis patients in relation to the multiple sclerosis risk-associated HLA-DR15 
haplotype. Assuming that the spectrum of self-peptides that is presented by the two 
HLA-DR15 allelic products is important for sustaining autologous proliferation we 
performed peptide elution and identification experiments from the multiple sclerosis-
associated DR15 molecules and a systematic analysis of a DR15 haplotype-derived 
self-peptide library. We identify HLA-derived self-peptides as potential mediators of 
altered autologous proliferation. Our data provide novel insights about perturbed T 
cell repertoire dynamics and the functional involvement of the major genetic risk 
factor, the HLA-DR15 haplotype, in multiple sclerosis. 
 
KEY WORDS: 





APCs = antigen presenting cells; BLS = bare lymphocyte syndrome; CNS = central 
nervous system; HD = healthy donor; HLA = human leukocyte antigen; IL = 
interleukin; MHC = major histocompatibility complex; PBMCs = peripheral blood 
mononuclear cells; TCR = T cell receptor 
 
INTRODUCTION 
Multiple sclerosis (MS) is considered a CD4+ T cell-mediated autoimmune 
disorder of the central nervous system characterized by inflammation, demyelination, 
glial scarring and axonal/neuronal loss (Sospedra and Martin, 2005). Regarding 
disease etiology, genome-wide association studies have identified a large number of 
genetic loci, which, together with multiple environmental factors, confer multiple 
sclerosis risk (Sawcer et al., 2011). The association between HLA-DR15 (formerly 
called DR2) and multiple sclerosis was first noticed in 1973 (Jersild et al., 1973), and 
since then has been among the most reproduced findings in major histocompatibility 
complex (MHC) genetics (Oksenberg et al., 2008). Furthermore, HLA-DR15 also 
influences clinical aspects like disease onset and phenotype (Hensiek et al., 2002). 
However, the mechanisms how the presence of a specific HLA-DR type, of other 
multiple sclerosis risk alleles and environmental factors translate to disease are 
largely unknown. Data from animal models and immunological studies in multiple 
sclerosis patients point at a role of autoreactive CD4+ T cells in multiple sclerosis 
(Sospedra and Martin, 2005). The most important, albeit indirect finding supporting 
this notion is the above fact that approximately 10 - 60% of the genetic risk stems 
from the HLA-DR15 haplotype consisting of two DR alleles, DRB1*15:01 (the 
heterodimer of DRA1*01:01/DRB1*15:01 is also referred to as DR2b) and 
DRB5*01:01 (the heterodimer of DRA1*01:01/DRB5*01:01 is also referred to as 
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DR2a) (Oksenberg et al., 2008). Interestingly, the influence of the environmental risk 
factors that have been identified for multiple sclerosis thus far, i.e. infection with 
Epstein-Barr virus, low vitamin D levels, and smoking, is enhanced in DR15+ multiple 
sclerosis patients (Kakalacheva et al., 2011).  
HLA-class II molecules are expressed by antigen-presenting cells (APCs). 
They present peptides derived from processing of self- or exogenous proteins, and 
the complexes of self HLA-class II and antigenic peptides serve as recognition 
structures for CD4+ T cells. In the thymus HLA-class II molecules are involved in 
shaping the CD4+ T cell receptor (TCR) repertoire through central tolerance 
mechanisms of positive- and negative selection of T cells (Ashton-Rickardt et al., 
1994). Once in the peripheral immune system the T cell repertoire is maintained alive 
by homeostatic proliferation, and interactions between CD4+ T cells and their TCRs 
with HLA-class II/self-peptide complexes as well as the cytokines interleukin-7 (IL-7) 
and IL-15 are the most important stimuli during this process (Sprent and Surh, 2011). 
Despite the well known role of HLA-class II in TCR repertoire generation and 
maintenance, our understanding about the functional contribution of HLA-class II 
molecules to human autoimmune diseases in general and also to multiple sclerosis 
is, however, still limited.  
Regarding possible mechanisms several hypotheses have been developed 
including preferential presentation of self-peptides with similarities to foreign antigens 
but also tissue-specific autoantigens (Wucherpfennig and Strominger, 1995), less 
complete thymic deletion of autoreactive T cells (Klein et al., 2000), and differential 
HLA-class II expression in certain immune cells and the brain (Prat et al., 2005). 
Another interesting possibility, which has not been examined thus far in multiple 
sclerosis, is that distinct structural features of the HLA-DR15 haplotype, i.e. of HLA-
DR molecules themselves or the complexes between HLA molecule and self-peptide, 
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operate via homeostatic proliferation and/or autologous expansion to shape an 
autoimmunity-prone T cell repertoire (Haegert, 2011). Homeostatic T cell proliferation 
depends on interactions between TCR and self-peptides presented by HLA 
molecules and the cytokines IL-7 and IL-15 (Sprent and Surh, 2011). Interestingly, 
genes coding for components of these and related molecules, i.e. DR15, IL7RA, IL-7, 
and IL2RA, are associated with multiple sclerosis risk (Sawcer et al., 2011).  
Evidence for alterations in CD4+ T cell selection and/or peripheral T cell 
repertoire maintenance in multiple sclerosis are: myelin-reactive T cells with a 
proinflammatory phenotype, lack of CD28 expression, and higher antigen avidity are 
increased in multiple sclerosis patients (Martin et al., 1990; Ota et al., 1990; Pette et 
al., 1990; Markovic-Plese et al., 2001; Bielekova et al., 2004). Further, reduced 
thymic output of CD4+ T cells has been observed in multiple sclerosis (Hug et al., 
2003; Duszczyszyn et al., 2006; Haegert et al., 2011) as well as reduced numbers 
and function of CD4+ T regulatory cells (Viglietta et al., 2004). Studies of the T cell 
repertoire by complementary region determining region 3 spectratyping indicate 
reduced diversity in multiple sclerosis patients compared to age-matched controls 
(Laplaud et al., 2004). These observations indicate alterations of the peripheral 
proliferation and survival/expansion of CD4+ T cells, which might affect antigen 
avidity and frequency of autoreactive T cells. Hence, alterations in T cell homeostasis 
could contribute to T cell repertoire perturbations in multiple sclerosis.  
 Given the prominent role of HLA-DR15 for multiple sclerosis risk, we therefore 
wanted to investigate its functional involvement in autologous T cell expansion in 
multiple sclerosis. For this purpose we devised an in vitro method to assess 
autologous proliferation. Different from the previously well examined autologous 
mixed lymphocyte reaction of human peripheral blood mononuclear cells (PBMCs), 
which is reduced in multiple sclerosis and other autoimmune diseases (Hafler et al., 
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1985), we did not expose autologous responder (T lymphocytes) cells to autologous, 
gamma-irradiated non-T cells as stimulators, but rather seeded unmanipulated 
PBMCs in a serum-free media. Hereby we addressed first, if autologous T cell 
proliferation is altered in multiple sclerosis patients in general and if there is a relation 
to the DR15 haplotype. Next, we dissected the relative role of self-peptides bound to 
DR2a and DR2b by two approaches, a) elution and identification of self-peptides 
bound to DR2a or DR2b, and b) based on the fact that HLA-derived-peptides 
themselves are frequently presented by HLA-class II alleles, we used overlapping 
peptides spanning the sequences of the two DR- and the DQ molecules of the DR15 
haplotype, i.e. the non-polymorphic DR chain DRA1*01:01, the two DR chains 
DRB1*15:01 and DRB5*01:01, and the tightly linked DQw6 molecule consisting of 
DQA1*01:02 and DQB1*06:02, as antigens. Our data demonstrate that autologous 
proliferation is increased in multiple sclerosis patients, which is related to the 
presence and dose of HLA-DR15 expression, that this phenomenon is observed with 
both DR alleles expressed in the DR15 haplotype and that HLA-class II-derived self-
peptides are likely involved as antigens.  
 
MATERIALS AND METHODS 
Patients and healthy donors 
Multiple sclerosis patients had clinically definite multiple sclerosis by clinical- 
and/or McDonald criteria. We examined 69 untreated multiple sclerosis patients, 8 
patients with clinically isolated syndrome (CIS), a prestage of relapsing-remitting 
multiple sclerosis (RR-MS), which often evolves into multiple sclerosis based on MRI- 
and clinical findings, 37 patients with RR-MS (8 of these in exacerbation), 8 
secondary-progressive multiple sclerosis (SP-MS) patients, i.e. the multiple sclerosis 
form that evolves from RR-MS, and finally 8 primary-progressive multiple sclerosis 
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(PP-MS) patients. A signed informed consent was obtained from all patients and 
donors under a protocol that was approved by the Ethics Committee of the Hamburg 
Board of Physicians (No. 2758). Samples were typed for HLA class II (DRB1*, 
DRB3*, DRB4*, DRB5*, DQA1* and DQB1*) at the Department of Transfusion 
Medicine, UKE Hamburg by a reverse SSO (Sequence Specific Oligos) in-house 
test. In some cases the results were verified by a commercial rSSO test (Dynal RELI-
SSO, Invitrogen) or by Atria SBT (Sequence Based Typing, Abbott). HLA-DR15+ 
indicates the haplotype HLA-DRB1*15:01, -DRB5*01:01, -DQA1*01:02 and –
DQB1*06:02. *X indicates another HLA class II haplotype, and *protective indicates 
HLA-DRB1*14 or –DRB*11 haplotypes (Ramagopalan et al., 2007). PBMCs were 
freshly isolated from EDTA-containing blood tubes or from buffy coats by Ficoll 
density gradient centrifugation (PAA, Pasching, Austria). All isolated PBMCs were 
cryopreserved in media containing 10% dimethyl sulfoxide (DMSO; AppliChem, 
Darmstadt, Germany) and stored at -180°C. 
 
Proliferative assays 
After thawing 2 x 105 PBMCs/well (average of 22 wells per donor) were 
cultured with serum-free AIM-V medium (GIBCO, Invitrogen), containing 2 mM L-
glutamine, 50 µg/ml streptomycin sulfate, 10 µg/ml gentamicin sulfate and human 
albumin, in 96-well U-bottom microtiter plates (Greiner Bio-One, Frickenhausen, 
Germany) at 37°C, 5% CO2. Depending on the experiment, wells were pulsed at day 
0, 2 and 6 cells for 15 hours with 1 µCi of methyl-3H-thymidine (Hartmann Analytic, 
Braunschweig, Germany), and incorporation was measured by -scintillation 
counting (Wallac 1450, PerkinElmer, Rodgau-Jürgesheim, Germany) (Suppl. Fig. 
1A). 1 µg/ml of PHA-L (Sigma, St. Louis, USA) was used as positive control.  
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HLA-DR15 haplotype-derived self-peptides were either tested in pools or 
individually at a 2 µM concentration (10 µM total pool concentration) in 7-day 
proliferation assays. Stimulatory indices (SI) were calculated as SI = mean cpm 
(counts per minute) (peptide) / mean cpm (unstimulated). Statistical analysis was 
performed using a student’s t test (two-tailed, unpaired) using Prism 5.0 software 
(GraphPad, La Jolla, USA). Analysis of the mean standard devations has been 
verified with tests for the homogeneity of variance (Fligner-Killeen, Bartlett, Levene), 
which have been performed using R (v 2.15.1) with libraries stats and car. 
 
HLA restriction  
CD4+ T cells were negatively enriched from thawed PBMCs of HLA-DR15+ 
HD donors using the IMag system (BD Biosciences, Heidelberg, Germany). 25.000 
CD4+ T cells (purity > 95%) were co-cultured for 3 days with 6.5 x 104 irradiated (200 
Gy) BLS cells in AIM-V serum-free medium. Restriction was tested with BLS cells 
transfected with a single HLA-class II molecule, DRB1*15:01 (DR2b - DRB1*15:01, 
DRA*01:01), DRB5*01:01 (DR2a - DRB5*01:01, DRA*01:01), DQw6 (DQA1*01:02, 
DQB1*06:02). BLS cells were kindly provided by G. Nepom and W. Kwok (University 
of Washington, Seattle, USA). Proliferation was assessed as described above. 
 
Blocking of autologous proliferation 
Autologous T cell proliferation was blocked by incubating PBMCs with anti-
HLA-class I (HLA-A, -B, -C; w6/32) and anti-HLA-DR (L243) antibodies at the 
depicted concentrations and compared to a purified mouse IgG2a low endotoxin, 
azide-free isotype control (BioLegend, MOPC-173, San Diego, USA) in a 3- and 7-
day proliferation assay.  
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Flow cytometry analysis 
Samples were thawed, Fc-blocked with mouse IgG and directly stained for 
surface expression using following antibodies: anti-CD3 (PE-Cy7, UCHT1, 
eBioscience, San Diego, USA), -CD4 (APC, RPA-T4, eBioscience), -CD8 
(PacificBlue, DK25, Dako, Glostrup, Denmark), -CD14 (PacificBlue, MP9, BD 
Pharmingen, San Diego, USA), -CD19 (PacificBlue, HIB19, BD Pharmingen), -
CD303 (APC, AC144, Miltenyi Biotech, Bergisch Gladbach, Germany), -panHLA-
class II (DR, DQ, DP) (FITC, Tü39, BD Pharmingen). Analyses were performed on a 
LSRII (BD Biosciences) flow cytometer using FACS Diva 5.0 software. 
 
Elution of HLA-presented peptides 
HLA-bound peptides were obtained by immunoprecipitation of HLA molecules 
from the BLS cell expressing only DR2a or DR2b according to standard protocols 
(Falk et al., 1991) using the DRB5*01:01-specific antibody (clone: H0596) for DR2a 
and the DRB1*15:01-specific antibody (clone: H0427A) for the DR2b cells. Both were 
provided by Jar-How Lee (One Lambda Incorporation, Canoga Park, USA). This was 
followed by a second HLA-precipitation by the pan-HLA-DR specific antibody L243 
for each cell lysate.  
About 3 ml cell pellet per cell line were gently shaken in 3 ml PBS containing 
1.2% (w/v) CHAPS in the presence of protease inhibitors (Complete Protease 
Inhibitor Cocktail Tablets, Roche Applied Science) for 1 hour followed by sonication 
of the lysate on ice with subsequent shaking for 1 hour. The lysate was centrifuged 
and the supernatant was passed through a 0.20 µm sterile filter. Subsequently, HLA 
molecules and bound peptides were isolated with the solid-phase bound monoclonal 
antibody by immunoaffinity chromatography (overnight at 4°C). HLA ligands were 
eluted with 0.2% trifluoroacetic acid, ultrafiltrated through a 10-kDa cut-off Amicon 
 10
ultracentrifuge filter, and lyophilized. 
 
Liquid chromatography-mass spectrometry 
Lyophilized samples were resuspended in 30 µl of solvent A (0.1 (v/v) formic 
acid in 2% (v/v) acetonitrile) and loaded onto a C18 precolumn (Dionex) for 
concentration and desalting with a flow rate of 20 µl/min. The precolumn was placed 
in line for separation by a 250 x 0.075 mm fused silica microcapillary column packed 
with C18 reversed-phase material (Acclaim PepMap 100, Dionex). A binary gradient 
of 0 to 55% solvent B was performed within 120 minutes, applying a flow rate of 300 
nl/min. 
The eluted peptides were analyzed by electrospray ionization (ESI) mass 
spectrometry on a linear trap quadrupole (LTQ) Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) coupled to nanoLC-2D (Eksigent) nano-HPLC system via 
a nanospray-ESI source. A gold-coated fused-silica glass capillary Picotip™ Emitter 
(SilicaTip™, FS360-20-10 Coating P200P, New Objective) was used for the 
introduction into the nanospray-ESI source.  The heated capillary temperature and 
spray voltage were held at 200°C and 1.9 kV, respectively, creating an electrospray 
between the Picotip and the transfer capillary resulting in a sample flow rate of 300 
nl/min. Parent ions were measured in the Fourier transform (FT) Orbitrap analyzer. 
Fragment ions were generated by collision-induced dissociation (CID) with 
normalized collision energy of 35 V and recorded in the LTQ. The activation time for 
CID was 30 ms. Mass spectrometry-survey scans were acquired at a resolution of 60 
000 at 400 m/z. The “lock mass” option (Olsen et al., 2005) was enabled for the FT-
mass spectrometry scans using the 445.120025 m/z ion for real time internal 
calibrations. The 5 most abundant parent ions from the FT survey scan were 
selected for fragmentation and excluded from further sequencing for 90 s. The mass 
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spectrometer was operated in positive ion mode and parent ions with an unknown or 
higher charge state than 3 were excluded from tandem mass spectrometry.  
 
Mass spectrometrical data analysis 
Tandem mass spectrometry data were analyzed with the Thermo Proteome 
Discoverer 1.1 (Thermo Fisher Scientific) software employing Mascot v2.2 (Matrix 
Science) as a search engine for peptide identification using a target-decoy database 
search in the Swiss-Prot protein sequence database (homo sapiens, release, 
2010_10). For database searches a mass tolerance of 5 ppm were used for FT-mass 
spectrometry scans whereas 0.5 Da were accepted for LTQ-MS/MS scans. The false 
discovery rate was set to ≤ 1%.  Phosphorylation of serine (S), threonine (T) and 
tyrosine (Y) as well as oxidation of methionine to methionine sulfoxide (m) were 
enabled as dynamic modifications. The software was allowed to group spectra if the 
retention time (RT) difference did not exceed 24 s.  
 
Peptide library generation and in silico peptide binding prediction 
122 overlapping (5 amino acid overlap) 15- and a few 16-mer peptides from 
DRB1*15:01, DRB5*01:01, DRA*01:01, DQA1*01:02, DQB1*06:02 
(http://hla.alleles.org) were synthesized and provided by pe (peptides & elephants 
GmbH, Potsdam, Germany). DR-chain-derived peptides with identical sequences 
were only synthesized once. Lyophilized peptides were resuspended in 100% DMSO 
and stored at -80°C.  
In silico peptide binding predictions were performed by the consensus 
approach provided by the Immune Epitope Database (www.iedb.org, (Wang et al., 
2008)). Gene Ontology annotation analysis of biological pathways was performed 
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Autologous proliferation is altered in multiple sclerosis patients 
We first characterized and compared in a standard thymidine incorporation 
assay the proliferation of PBMCs from 69 untreated multiple sclerosis patients and 36 
healthy donors (HD; for demographics see Suppl. Table 1) over seven days in 
serum-free media. Below, we will refer to this condition in the absence of a stimulus 
as autologous proliferation. Since there is no background control and a stimulation 
index cannot be calculated, we expressed the strength of proliferation by the mean 
counts per minute (cpm) of all wells (Fig. 1A) and the variation or heterogeneity by 
the mean, amongst multiple donors within each group, e.g. multiple sclerosis or 
controls, of the standard deviation of all wells within each donor (Fig. 1B; schematic 
depiction in Fig. 1C). PBMCs from multiple sclerosis patients incorporated 
significantly more thymidine (mean cpm ± SEM, 5337 ± 548) than HD (3606 ± 503, P 
= 0.04), while no differences in strength of proliferation were observed after PHA 
stimulation (Fig. 1A). PBMCs from multiple sclerosis patients not only incorporated 
more thymidine, but also the variation between wells was significantly higher or 
heterogeneous (SD ± SEM, 2099 ± 217) than in HD (1422 ± 180, P = 0.04) (Fig. 1B), 
and again no differences in heterogeneity were observed after PHA stimulation (data 
not shown). Some wells from multiple sclerosis patients proliferated as vigorously as 
usually observed upon stimulation with nominal antigen (Fig. 1C), suggesting that 
some T cells from multiple sclerosis patients are activated in the absence of a 
stimulus. We then compared patients with different forms of multiple sclerosis, i.e. 
clinically isolated syndrome (CIS), a pre-stage of multiple sclerosis, relapsing-
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remitting multiple sclerosis (RR-MS) in remission (RR-MS-remission) or in 
exacerbation (RR-MS-relapse), secondary-progressive multiple sclerosis (SP-MS) 
and primary-progressive multiple sclerosis (PP-MS). The differences of the strength 
of proliferation were similar in the subgroups, while the heterogeneity measure was 
higher for CIS- and RR-MS patients in relapse (Suppl. Fig. 1B). In order to exclude 
that a leuko- or lymphopenic condition of the donors/patients with increased 
autologous proliferation elicited homeostatic proliferation, i.e. growth of T 
lymphocytes to fill an empty or partially emptied niche, we performed differential 
blood counts on all donors. Only two HD showed lymphocyte counts slightly below 
normal values, and there was no correlation between peripheral blood white cell- or 
lymphocyte counts and the degree of autologous proliferation (data not shown). 
 
Increased autologous proliferation is related to the multiple sclerosis-
associated DR15 haplotype 
 We next addressed the involvement of the HLA-DR15 haplotype in the above 
findings. As shown in Figure 2A, the strength of autologous proliferation (mean cpm) 
was higher in DR15+ individuals than in DR15- when comparing all studied 
individuals (left panel) and also in multiple sclerosis patients versus HD, although 
differences were only significant for DR15- HD versus DR15+ multiple sclerosis 
patients (second panel from left; P = 0.045). The differences were more pronounced 
for the proliferation heterogeneity (mean SD) of all studied DR15+ versus DR15- 
individuals (second panel from the right; P = 0.004) and for both DR15- versus 
DR15+ HD (right panel; P = 0.047) and DR15- versus DR15+ multiple sclerosis 
patients (right panel; P = 0.036) indicating that autologous proliferation strength and -
heterogeneity increase with disease- and HLA-DR15 status, which is particularly 
clear from the “single-well” view of PBMCs (Fig. 2B). Here, each column represents a 
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single donor with all seeded wells. Each well is represented by a white dot. Donors 
were sorted by the well with the highest cpm count and according to disease and 
HLA status. Supplementary Table 1 summarizes the results of Figure 2A and 2B. 
 
Characterization of autologous proliferating cultures 
In order to characterize better, which cell population in the peripheral blood 
mononuclear cells is responsible for autologous proliferation we determined the 
percentage of CD4+, CD8+ and memory CD4+ T cells before and after 7 days of in 
culture. As expected autologous proliferation was primarily mediated by CD4+ T 
cells, since their percentages were high at the time of starting the assay and 
increased further until day 7 (Fig. 3A, left panel), while the initially low numbers of 
CD8+ T cells dropped (Fig. 3A, third panel from left) indicating that under uninhibited 
culture conditions CD8+ T cells did not proliferate to a significant extent. Further, we 
did not observe major changes regarding the naïve/memory CD4+ T cell population 
composition (Fig. 3A, second panel). However, the slight but consistent decrease of 
CD4+CD45RO+ T cells indicates that autologous proliferation is mediated to a larger 
extent by naïve-, i.e. CD4+CD45RO-, then by memory T cells.  
 Next we wanted to address the potential contribution of the level of baseline 
HLA-DR expression or its upregulation during the culture period. As shown in Fig. 3A 
(right panel), DR expression on B cells increased significantly, supporting a putative 
role of HLA-DR in the above phenomena (Fig. 3A, right panel). We then asked 
whether a higher baseline HLA-DR/DR15 expression on APCs is a consequence of 
for example a proinflammatory environment in multiple sclerosis and then causes 
increased homeostatic proliferation. Toward this aim we examined the HLA-class II 
expression (DR, DP and DQ) on plasmacytoid dendritic cells, monocytes and B cells 
in HD and multiple sclerosis patients homozygote or heterozygote for DR15 as 
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indicated by Cella et al. (Cella et al., 1997). HLA-class II expression did not differ 
significantly between donors with the exception of lower levels of HLA-DR expression 
on monocytes of multiple sclerosis patients (Fig. 3B, middle panel). Also, there was 
no DR-related gene dosage effect in DR15 homozygous versus heterozygous 
multiple sclerosis patients or HD. Finally, blocking antibodies against HLA-class II 
alone (Fig. 3C, left panel) and against both HLA-class I and -class II (Fig. 3C, right 
panel) reduced the autologous proliferation in a dose-dependent manner both at day 
3 and day 7 (Fig. 3C). Together these data indicate that interactions between CD4+ 
T cells and their TCR with self HLA-class II molecules are involved in autologous 
proliferation, that B cells may play a role in this phenomenon in vitro and that different 
levels of HLA-class II expression at baseline are unlikely to be involved.  
  
Elution of HLA-DR-derived self-peptides from the DR alleles expressed in the 
multiple sclerosis-associated DR15 haplotype 
 The above observations point at an involvement of the two DR15 alleles, 
DRB1*15:01 (DR2b) or DRB5*01:01 (DR2a) and the self-peptides they display in 
increased autologous T cell proliferation in DR15+ multiple sclerosis patients. 
Multiple factors could contribute to this observation including a genetically 
determined lower activation threshold of T cells in multiple sclerosis and a TCR 
repertoire that is shaped in DR15+ individuals by central tolerance mechanisms, 
which has higher affinity for DR15/self-peptide complexes. With respect to the latter, 
structural features of the DR molecules, i.e. their contact surfaces with the TCR of 
CD4+ T cells, or the spectrum of bound self-peptides or both could play a role. To 
address the latter aspect we next examined the nature of self-peptides and their 
potential role in increased autologous proliferation by characterizing self-peptides 
that are bound to DR2a and DR2b by peptide elution and sequencing by mass 
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spectrometry (schematically shown in Fig. 4A). In a prior study, we had employed 
Epstein-Barr virus-transformed B cell lines that co-expressed all alleles of the DR15 
haplotype using a monoclonal antibody against monomorphic determinants of DR 
alleles (Vogt et al., 1994). To focus on DR2a and DR2b directly, we here used bare 
lymphocyte syndrome (BLS) patient-derived B cell lines that had been transfected 
with either DR2a or DR2b and did not express any other HLA-class II molecule. 
Furthermore, for precipitation of DR2a and DR2b molecules we used allele-specific 
monoclonal antibodies against DR2a or DR2b, respectively. Due to the lower 
precipitation efficiency of the latter IgM antibodies, a second sequential 
immunoprecipitation was performed with the L243 antibody. Since BLS transfectants 
only express one class II allele, the peptide elution presumably underestimates the 
relative presence of HLA-class II-derived peptides by limiting the number of available 
class II molecules. We eluted and identified a total of 154 peptides from DR2a and 
DR2b molecules (Fig. 4A; Suppl. Table 2), and 7.14% (w/o considering multiple 
protein hits) of these peptides were derived from DR (DRA1*01:01) or the  chains 
of DR2b (DRB1*15:01) or DR2a (DRB5*01:01). Hence, HLA-class II molecule-
derived self-peptides form a substantial fraction of the spectrum of self-peptides that 
are bound to the multiple sclerosis-associated DR15 alleles. Biological pathway gene 
ontology annotation of the eluted peptides demonstrated that many of them are 
assigned to the antigen presentation pathway (Suppl. Table 3). Herewith we confirm 
and broaden our earlier results that HLA-class II-derived self-peptides make up a 
considerable portion of the peptide spectrum presented by DR2a and DR2b (Vogt et 
al., 1994).  
 
Reactivity to HLA-DR15 haplotype-derived self-peptides is related to 
expression of the haplotype itself 
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 The above data indicate that HLA-derived self-peptides probably participate in 
autologous proliferation and also in T cell activation/stimulation beyond autologous 
turnover. To address this point we generated a HLA-DR15 haplotype-derived self-
peptide library consisting of 15-mer peptides with 5 amino acids overlap spanning the 
whole HLA-DR15 haplotype protein sequence (Fig. 4B). The resulting 122 peptides 
were derived from 5 proteins, i.e. the polymorphic chains HLA-DRB1*15:01 (DR2b), -
DRB5*01:01 (DR2a), the conserved HLA-DRA*01:01, and the HLA-DQw6 molecule 
consisting of HLA-DQA1*01:02 and -DQB1*06:02 (Fig. 4B, Suppl. Table 4). HLA-
DRβ chains share most of their sequences and are only polymorphic in certain areas, 
and therefore peptides derived from shared sequences were only synthesized once 
(Fig. 4B and C).  
Since the relative genetic risk conferred by the multiple sclerosis-associated 
HLA-DR15 haplotype correlates not only with DR15 carrier status, but also with its 
dose, i.e. homo- versus heterozygosity (Barcellos et al., 2003; Cournu-Rebeix et al., 
2008) we used the entire HLA-derived peptide library, i.e. 24 pools of 5 peptides 
each, to stimulate PBMCs from multiple sclerosis patients/HD (20 donors each) that 
were stratified according to DR15 homo- and heterozygosity (Fig. 5A). Since large 
genetic studies had indicated that there are also HLA-DR alleles that are “protective” 
for multiple sclerosis, e.g. the HLA-DR14 haplotype (Ramagopalan et al., 2007), we 
included a HLA-DR15/”protective” cohort (HLA-DRB1*14, -DRB1*11), which should 
have the lowest risk for multiple sclerosis development regarding HLA background. 
We did not find these “protective” DR alleles among our multiple sclerosis patients, 
and therefore only tested HD. Figure 5A depicts the % of wells with an SI > 2.0 of all 
peptide pools tested for the different donors. While the differences did not reach 
statistical significance (Fig. 5A, left panel), there is a clear trend that the reactivity 
increases from protective DR allele carriers to DR15 heterozygous- to homozygous 
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DR15 carriers. Due to the higher background/autologous proliferation in multiple 
sclerosis patients (see above), which affects the calculation of the stimulatory index 
(SI), effects are more pronounced in HD. In addition, we tried to capture not only 
proliferating cells according to standard criteria, i.e. surpassing background 
proliferation by at least a factor of two (SI > 2), but also those showing a “low-grade” 
proliferation (defined as SI > 1.4). Since we added here nominal peptide in distinction 
to the above unstimulated condition, which we referred to as autologous proliferation, 
we will from now on refer to the peptide-induced “low-grade” proliferation as “tonic” 
stimulation. As shown in Fig. 5A (middle panel), the tonic stimulation also increases 
in relation to DR15 haplotype and homozygosity. 
 
Potential role of HLA-DR15 haplotype-derived self-peptides in autologous T 
cell proliferation 
Next, we assessed the stimulatory- or inhibitory potential of the HLA-derived 
self-peptides (Fig. 5B). Selected individual HLA-DR15-derived self-peptides were 
tested after analyzing the proliferation of 35 Donors (20 multiple sclerosis, 15 HD) to 
the 24 pools of self-peptides (Suppl. Fig. 2). Additionally, since they are most likely to 
be presented in vivo, we also tested two peptides, which had been eluted. Peptide 8 
(SDVGEFRAVTELGRP) and its DR2a-homologue had been eluted twice, by Vogt et 
al. (Vogt et al., 1994) and again from DR2a in the present study. Peptide 54 
(EEFGRFASFEAQGAL) was eluted from HLA-DR2b. Like peptides 14, 15, 20, 45, 
both elicited strong T cell proliferation (Fig. 5B, left panel). These experiments 
demonstrate that distinct DR15 haplotype-derived self-peptides are stimulatory to 
bulk PBMCs, while other peptides seem to inhibit activation or proliferation (SI > 2.0). 
As described in Figure 5A, we used the thresholds of SI > 2.0 and > 1.4 respectively 
to discriminate between activation and tonic proliferation. When looking at one 
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specific peptide as example, peptide 45, 12.5% of all wells proliferated with SIs > 2.0 
(Fig. 5C) and 66% with SIs > 1.4 (not shown) indicating that a large number of wells 
responds with a tonic proliferation pattern, and a fraction of cells is fully activated. 
Interestingly, peptide 45 showed a marked T cell response despite originating from 
the inhibitory pool number 9 supporting the consideration that inhibitory and 
stimulatory peptides within each pool interact, consequently explaining the low 
overall proliferative response to the peptides pools (Suppl. Fig. 2). 
We further asked if the stimulatory HLA-DR15-derived self-peptides could, if 
pooled together, evoke a stable T cell proliferation and if so, which concentrations 
are sufficient to induce proliferation. For this purpose different doses between 0.1 
and 20 µM of a pool of five strongly stimulatory peptides were used. Peptide 54 had 
been eluted, peptides 8 and 20 were analogues of eluted peptides, and peptides 14 
and 45 demonstrated the strongest tonic proliferation stimulus in the above 
proliferative assays with individual peptides. As shown in Fig. 5C, the pool of 
stimulatory peptides led to full stimulation and also tonic proliferation over a wide 
range of concentrations with a peak at 1.0 µM (Fig. 5C). 
Next, we used the above five stimulatory peptides and examined the HLA-
class II restriction using purified CD4+ T cells and BLS transfectants expressing 
either DR2b, DR2a or DQw6. Most of the peptides elicited their stimulatory effect 
when presented by HLA-DR2a (Fig. 5D, dark grey). Interestingly, when they were 
added to APCs expressing HLA-DQw6, most peptides showed inhibitory rather than 
stimulatory effects.  
  
Characterization of polymorphic HLA-DRβ-derived peptides 
Finally, we compared corresponding peptides derived from the polymorphic 
regions of the two DRβ chains (Fig. 6A; see also Fig. 4C). We found significant 
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differences in 5 of 10 pairs (Fig. 6A). In 4 of the 5 pairs DR2b-derived peptides (Fig. 
6A, light grey) were more stimulatory, while we found the reverse, i.e. that the DR2a-
derived peptide was more stimulatory, only for peptide 44 versus peptide 22. Peptide 
4 (DTRPRFLWQPKRECH, DR2b-derived) gave the strongest proliferative response 
of all polymorphic peptides. Figure 6B summarizes all allele-specific DRβ chain-
derived peptides, which we compared in Figure 6A. In order to understand better, if 
these peptides bind to either of the two DR15 molecules, DR2a and DR2b, or to 
DQw6, we performed well-established in silico peptide binding predictions. The 
predicted binding affinities (% consensus rank; low values indicate better binding; 
highest affinity highlighted in green) are summarized in Figure 6B, and we further 
mention if the respective peptide was eluted from DR15 molecules in this or our prior 
study (Vogt et al., 1994). Table 2 additionally analyzes peptides that have been 
eluted or shown to be stimulatory in our experiments. Both tables (Figure 6B and C) 
depict the peptide origin and the probability of being presented by an HLA-class II 
molecule of the DR15 haplotype. It is interesting to note that, while more of the 
stimulatory polymorphic peptides derive from the DR2b allele, the predicted binding 
affinities of these peptides are higher for binding to DR2a and, consistent with this, 
the peptides have been eluted from DR2a. 
 
DISCUSSION  
 Despite substantial progress in immunology we still know remarkably little 
about how certain HLA-class II alleles contribute to autoimmune diseases (Gronski et 
al., 2004; McFarland and Martin, 2007). HLA-DR15 as major risk factor for multiple 
sclerosis is one of the most striking examples for this notion. The mechanisms as to 
how HLA-DR15 shapes and maintains an autoreactive T cell repertoire that leads to 
central nervous system (CNS) autoimmunity are still elusive despite longstanding 
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efforts by a number of groups including our own, which focused primarily on studying 
the antigen specificity, function and HLA restriction of autoreactive T cell clones. In 
the present study we explored a hypothesis that had been discussed earlier in the 
context of autoimmune liver disease (Burroughs et al., 1992) and oligoarticular 
juvenile idiopathic arthritis (Massa et al., 2002) but not for multiple sclerosis so far. 
These studies postulate that self-peptides derived from and presented by abnormally 
expressed HLA-class II molecules potentially mimic microbial/viral peptides and may 
serve as target for the autoimmune T cell responses. Based on the consideration that 
interactions between HLA-class II molecules and the TCRs of CD4+ T cells are 
besides IL-7 the most important factor to keep peripheral T cells alive, we examined 
the functional involvement of the HLA-DR15 haplotype in shaping and/or maintaining 
the peripheral T cell repertoire in multiple sclerosis via autologous proliferation. It has 
to be clarified, however, that we cannot assess by our simplified in vitro system the 
complex in vivo interactions that lead to T cell repertoire maintenance. Different from 
the steady-state in vivo homeostatic proliferation, i.e. in the absence of lymphopenia, 
which involves HLA/MHC/self-peptide complexes and/or IL-7 depending on the cell 
type (Baccala and Theofilopoulos, 2005; Cox et al., 2005), our assay system most 
likely depicts a combination of autologous activation and subsequent proliferation in 
the absence of any stimulus. As stated above, this setting is different from the well-
examined autologous mixed lymphocyte reaction, where antigens that are generated 
by apoptosis of the irradiated stimulator cells are recognized by autologous T cells 
(Amel Kashipaz et al., 2002), which probably also explains the divergent results 
between autologous mixed lymphocyte reaction in multiple sclerosis, i.e. decreased 
proliferation (Hafler et al., 1985), and our observation of increased autologous 
proliferation. 
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With advanced age thymic output decreases, and hence compensatory peripheral 
homeostatic proliferation becomes more important for maintaining a functional T cell 
repertoire (Naylor et al., 2005). Previous studies have described earlier thymic 
involution as well as reduced generation of CD4+ recent thymic emigrants in multiple 
sclerosis (Duszczyszyn et al., 2010). Here, we show elevated autologous T cell 
proliferation in patients with multiple sclerosis compared to HD in our experimental in 
vitro system. The autologous proliferation is more heterogeneous in that a substantial 
fraction of cells shows signs of full activation in multiple sclerosis patients, and it is 
related to the multiple sclerosis-associated HLA-DR15 haplotype. Based on the 
importance of HLA-class II molecules, presented self-peptides, and the TCR avidity 
(Sprent and Surh, 2011) for this process, we assume that the HLA-DR15 haplotype is 
involved in altered homeostatic T cell proliferation in multiple sclerosis. Since the 
multiple sclerosis patients of this study were not lymphopenic, i.e. did not have a 
relative depletion of the lymphocyte niche, it appears that lymphocytes are not 
numerically reduced, but rather that their repertoire is more narrow with respect to 
different specifities, but enriched for T cells with higher affinity for self-peptide. Such 
a repertoire is then expected to be activated easier in an autologous setting, which is 
simulated by our in vitro system.   
Although immune mechanisms exist that sustain a T cell repertoire of great 
diversity (Min et al., 2004) previous studies have reported that the peripheral 
maintenance of naïve T cells is not random (Rudd et al., 2011). Under homeostatic 
conditions TCR affinity/avidity appears to regulate T cell survival (Kieper et al., 2004). 
In line with these concepts, we have previously shown that the presentation of self-
peptides by mature DCs can lead to a state of preactivation of T cells (Kondo et al., 
2001). Together, these studies emphasize that homeostatic/autologous proliferation 
supports mechanisms of selection and preferential activation of certain parts of the T 
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cell repertoire. Therefore, the heterogeneous autologous proliferation with some cells 
showing a tonic response and others signs of full activation could indicate a process 
of selection through predominant proliferation of certain sets of T cells expressing 
TCRs with higher avidities for self-MHC/self-peptide complexes.  
During T cell activation the TCR contacts both antigenic peptide and HLA-
backbone. The two alpha-helices of the HLA-backbone represent over 60% of the 
TCR:MHC/peptide interaction surface (Sundberg et al., 2007). When dissecting the 
trimolecular complex (TCR:MHC/peptide), the following considerations are important. 
First, the higher the contribution of the MHC backbone to overall avidity the higher 
the number of peptides that can be recognized by the TCR. Second, since T cell 
activation (or prevention of death) is related to TCR affinity, selection is a 
consequence of homeostatic T cell proliferation. Third, the composition of self-
peptides that are presented by a given HLA molecule is constrained by structural 
aspects of its binding pockets. Fourth, the presenting HLA molecule itself, which 
passes through the main processing compartments, is an important source of 
peptides that are displayed in its own binding pockets (Dengjel et al., 2005). 
Therefore, HLA haplotypes present a haplotype-specific diverse set of self-peptides, 
which probably participates in shaping the peripheral T cell repertoire. Since our in 
vitro studies show that the heterogeneity of proliferation was enhanced by the HLA-
DR15 haplotype, we hypothesize that either the structural configuration of the HLA 
backbone, the self-peptides presented by the HLA-DR15 haplotype, or a combination 
of both are at least in part responsible for the observed proliferation patterns.  
Most of the time surface HLA-class II molecules are loaded with self-peptides 
(Schild et al., 1990). To analyze the potential role of self-peptides derived from the 
multiple sclerosis-associated HLA-DR haplotype and thus address some of the 
above possibilities, we eluted peptides presented by the HLA-DR15 haplotype. 
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Consistent with prior work including ours’ (Vogt et al., 1994; Dengjel et al., 2005) we 
identified self-peptides from various sources and mostly from processing- and 
antigen presentation-related molecules. Among the latter a substantial fraction was 
derived from molecules of the HLA-DR15 haplotype itself. Our data indicate that 
HLA-derived self-peptides play an important role in the observed HLA haplotype-
specific differences in autologous proliferation and that they can promote T cell 
proliferation. By using systematically generated sets of peptides spanning all DR- 
and DQ - and  chains, we demonstrate that relatively high frequencies of 
peripheral T cells recognize certain HLA-derived self-peptides. While T cell 
proliferation is often tonic, full activation is not a rare event even without any 
antigenic stimulus in PBMCs from multiple sclerosis patients. These data indicate 
that HLA-DR15-derived self-peptides are able to provide a low-level stimulus or fully 
activate parts of the peripheral T cell repertoire. Furthermore, the observed HLA-
derived peptide reactivity correlated with the genetic risk conferred by the HLA-DR 
haplotype. In individuals, who are haploidentical with respect to HLA-class II type, the 
combined effects of stimulatory and inhibitory self-peptides derived from multiple 
sclerosis risk-conferring and/or -lowering HLA alleles probably participates in setting 
the activation thresholds of T cells. 
Positively selecting self-peptides in the context of CD4+ T cells have recently 
been described in murine models (Lo et al., 2009), and the most important 
conclusions from these studies were the high specificity in the recognition of 
positively selecting ligands and that the same self-peptides can support peripheral 
homeostatic proliferation or serve as coagonists in the recognition of nominal ligand 
(Krogsgaard et al., 2007; Wucherpfennig and Gagnon, 2009). Since the number of 
self-peptides that are involved in thymic selection processes is considered to be 
small, and many of these are presented both on thymic- and peripheral APCs, they 
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are probably relevant in both contexts, i.e. during central selection and peripheral 
homeostasis. Although thymic T cell repertoire selection appears to depend primarily 
on TCR:MHC/peptide affinity, the peripheral maintenance and selection is 
determined by TCR cross-reactivity (Hao et al., 2006). Regarding the latter, the TCR 
cannot distinguish between self- and non-self peptides (Ashton-Rickardt et al., 1994; 
Krogsgaard et al., 2007), and therefore self-peptides presumably are a major factor 
in shaping and maintaining the composition of the peripheral T cell repertoire. Since 
HLA molecules bind different sets of peptides based on the structural requirements of 
their binding pockets (Falk et al., 1994), different self-peptide repertoires will be 
presented according to haplotype. These factors together with the structural 
characteristics of the exposed surface of HLA molecules most likely lead to HLA-
haplotype-specific shaping of the T cell receptor repertoire.  
Besides these structure-related possibilities our data point at yet another one, 
which involves peptides derived from the non-polymorphic or polymorphic stretches 
of HLA molecules as antigens themselves. Interestingly, an earlier study on the role 
of polymorphic regions of different DRB1* alleles including DRB1*15:01 observed 
significant multiple sclerosis-association of the amino acids proline at position 11, 
arginine at position 13, and alanine at position 71 of HLA-DRB1*15:01 (Zipp et al., 
2000). This study did not examine the DRB5* allele nor the abovementioned 
structural contributions or role of a polymorphic DR-derived peptide as antigen. In our 
present study, HLA-derived peptide number 4 contains both proline at position 11 
and arginine at position 13, and therefore this peptide could contribute to increased 
autologous proliferation by shaping the binding pocket of DR2b, or conversely it 
could be an antigen itself. Peptide 4 was the most stimulatory of the polymorphic 
areas (see Fig. 6B), while the homologous peptide 30 derived from the same area of 
DRB5*01:01 was not stimulatory.  
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If one attempts to link these findings to multiple sclerosis, it is currently 
believed that autoreactive T cell responses in multiple sclerosis are directed against 
myelin proteins including myelin basic protein (MBP) (Sospedra and Martin, 2005). 
Early studies by others and us have found MBP-specific T cells in multiple sclerosis 
patients, but also in healthy controls (Martin et al., 1990; Ota et al., 1990; Pette et al., 
1990). Despite higher precursor frequencies in multiple sclerosis patients in some 
studies this observation at first seemed to argue against a role of these cells in 
multiple sclerosis, but later studies not only described higher frequencies, but also 
other potentially relevant characteristics such as higher functional TCR avidity 
against several myelin peptides derived from MBP, myelin oligodendrocyte 
glycoprotein (MOG) and proteolipid protein (PLP) (Bielekova et al., 2004), 
populations that are independent of costimulation (Markovic-Plese et al., 2001), signs 
of activation (Bielekova et al., 1999) and enrichment in the naïve CD4+ T cell 
compartment (Muraro et al., 2000). An interesting question is if the increased 
autologous turnover that we describe here, also leads to conversion to memory 
phenotype in autoreactive T cells, which would explain the increased numbers of 
MBP-specific memory cells in multiple sclerosis patients (Burns et al., 1999). In line 
with this speculation, investigations of the CD8+ T cell compartment show that T cell 
numbers and diversity decrease with age, surviving T cells undergo faster rates of 
homeostatic proliferation, are selected for high TCR avidities, and preferably acquire 
“memory-like” phenotype (Rudd et al., 2011). The relatively early thymic involution 
that was described in multiple sclerosis (Duszczyszyn et al., 2010) could lead to an 
increased demand for compensatory peripheral homeostasis in the CD4+ 
compartment as observed in the autologous proliferation setting. A combination of 
the presented HLA-haplotype-specific self-peptides and structural features of the 
HLA-DR15 haplotype may lead to alterations in the overall strength and quality of 
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proliferation with the consequence of selecting an “autoimmune-prone” T cell 
repertoire.  
Another important aspect is the question if only DRB1*15:01 or also 
DRB5*01:01 determines multiple sclerosis risk. A number of studies indicate the 
former, i.e. that risk is only conferred by DRB1*15:01 (Caillier et al., 2008). We favor 
that both alleles contribute jointly to multiple sclerosis risk based on the similarities of 
the peptide binding motifs (Vogt et al., 1994; Wucherpfennig et al., 1994), which lead 
to presentation of similar peptides including the immunodominant MBP peptide83-99, 
which can be presented equally well by both alleles (Martin et al., 1991; Valli et al., 
1993; Wucherpfennig et al., 1994). Also, humanized transgenic mice expressing a 
multiple sclerosis patient-derived MBP83-99-specific TCR and DR2a (DRB5*01:01) 
develop spontaneous experimental autoimmune encephalomyelitis (Quandt et al., 
2012) as do transgenic mice expressing a MBP84-102-specific TCR and DR2b 
(DRB1*15:01) (Madsen et al., 1999). Furthermore, myelin-specific- and virus-specific 
T cell clones, which recognize the same and different peptides in the context of both 
DR2a and DR2b, have been described (Lang et al., 2002; Sospedra et al., 2005), 
and that their cross-restriction leads to higher antigen avidity (Sospedra et al., 2006; 
Yousef et al., 2012). Here, we observe that the majority of HLA-derived polymorphic 
peptides that stimulate T cell proliferation are derived from DR2b (e.g. peptides 4 and 
8), however, when examining their peptide binding to the two DR molecules, both 
show stronger affinity, are restricted by and have been eluted from DR2a (Fig. 6). We 
observed the reverse with peptide 45. Finally, we found non-polymorphic peptides, 
i.e. peptide 54 derived from DRA1*, which is predicted to bind better to DR2b and 
which we had also previously eluted from DR2b (Fig. 6C), although the bulk CD4+ T 
cells recognize the peptide when presented by DR2a (Fig. 6A). These data do not 
answer definitively the above question, which of the two alleles is more relevant for 
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shaping an autoimmune-prone T cell repertoire in DR15+ multiple sclerosis patients, 
but they support the notion that both are involved.  
Taken together, our observations are in line with previous reports describing 
early thymic involution and repertoire narrowing in patients with multiple sclerosis. 
The subsequent demand for an increased peripheral maintenance and the 
accompanying effects on TCR repertoire selection are reflected not only in the 
enhanced-, but also in a more heterogeneous proliferation pattern. Further, we 
demonstrate that the HLA-DR15 haplotype-derived self-peptides and/or structural 
features of the two HLA-DR molecules of the DR15 haplotype are likely involved in 
increased autologous proliferation. It remains to be shown if T cells that are 
expanded by autologous proliferation have the propensity to cross-react with myelin- 
or CNS autoantigens as indicated by (Cai and Hafler, 2007), can be activated by 
peptides from foreign agents and if the autologous proliferation leads to preferential 
differentiation into proinflammatory T cells. There are probably additional factors that 
contribute to the proliferation patterns including cytokine receptors, cytokines, 
costimulatory molecules and their ligands, CD4-HLA-class II co-receptor interactions, 
and integrin/adhesion molecules, which may all be involved in regulating the 
threshold for T cell activation, -expansion or functional differentiation. Interestingly, 
single nucleotide polymorphisms of a number of these (IL7RA, IL2RA, IL7, CD58, 
CBLB, CD40, IL12B, IL22RA2, and others) have been found to be involved in 
multiple sclerosis risk (Sawcer et al., 2011). Based on our observations and the 
genetic data, we propose the following model. The two DR alleles in the DR15 
haplotype and as yet unknown self-peptides select by central tolerance mechanisms 
a TCR repertoire that has the inherent propensity to recognize CNS autoantigens 
and lead to a CNS-specific autoimmune T cell response. Positively selected T cells 
are maintained and/or expanded by peripheral homeostatic proliferation, which again 
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involves the two DR15 alleles and according to our data among the spectrum of self-
peptides also those derived from the DR15 haplotype themselves. Both a genetically 
predetermined lower activation threshold and certain environmental triggers then 
finally lead to full activation and expansion of CNS-autoreactive T cells, their 
proinflammatory differentiation and eventually the development of multiple sclerosis.  
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FIGURE LEGENDS 
Figure 1. Comparison of autologous proliferation of peripheral mononuclear 
cells. Significant differences in proliferation strength (A) (mean cpm ± SEM) and 
heterogeneity (B) (standard deviation ± SEM) are observed between multiple 
sclerosis (MS) and healthy donors (HD) at day seven (* indicating P-value of < 0.05). 
(A) Right bar graph depicting the PHA positive control. (C) Example of one multiple 
sclerosis donor showing all unstimulated wells over a seven-day proliferation assay 
with adjacent scheme explaining measures of proliferation strength and 
heterogeneity. 
 
Figure 2. Influence of HLA-DR15 haplotype on autologous proliferation. (A) 
Proliferation strength is shown for multiple sclerosis (MS) and healthy donors (HD) 
together (left graph) or subdivided into HLA-DR15 haplotype-positive and -negative 
patients and HD (right graph)(mean cpm ± SEM). (B) Proliferation heterogeneity is 
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shown for multiple sclerosis and healthy donors together (left graph) or subdivided 
into HLA-DR15 haplotype-positive and -negative patients and HD (standard deviation 
± SEM). (B) Each column represents one donor with dots displaying every single 
unstimulated well (thymidine incorporation at day 7; * indicating P-value of < 0.05, 
average wells per donor = 22).  
 
Figure 3. T cell subpopulations and HLA-DR expression: (A) FACS analysis of 
CD4+, CD4+ CD45RO+ and CD8+ surface expression on CD3+ T cells as well as 
the HLA-DR expression changes on B cells during seven days of unstimulated 
PBMCs proliferation of 5 HD. (B) HLA-class II expression (median fluorescent 
intensity; MedFI) on different APCs of HLA-DR15-positive and -negative multiple 
sclerosis patients (MS) and HD: CD303+ plasmacytoid dendritic cells, CD14+ 
monocytes and, CD19+ B cells. (C) Blocking of autologous proliferation using anti-
HLA class I- and -DR-specific antibodies. Inhibition of proliferation was measured on 
day 3 and day 7 and is shown as % of uninhibited proliferation. 
 
Figure 4. HLA-DR2a and –DR2b-specific peptide elution and characterization, 
and HLA-DR15 haplotype-derived self-peptide library. (A) Schematic drawing of 
peptide elution from BLS cells expressing only DRB1*15:01 (DR2b) or DRB5*01:01 
(DR2a), respectively. (B) Pictogram illustrating the composition of the HLA-DR15 
haplotype-derived library of self-peptides (15mers). (C) Exon 2 sequences of 
DRB1*15:01 and DRB5*01:01. Origin of allele-specific DRβ chain-derived peptides 




Figure 5. Proliferation of peripheral blood mononuclear cells upon stimulation 
with HLA-DR15 haplotype-derived self-peptides. (A) % positive wells tested 
against 24 pools of HLA-DR15-derived self-peptides. Multiple sclerosis (MS) patients 
(MS risk n = 10, MS hetero n = 10) and HD (HD risk n = 7, HD hetero n = 8, HD 
protective n = 5) were stratified according to HLA-DR15 status as depicted by the 
schematic on the right. Risk indicates homozygosity for HLA-DR*15, hetero indicates 
HLA-DR*15/*X, and donors with protective alleles carry HLA-DR*15/*14 or -*11 
haplotypes. % positive wells with SI > 2.0 (left graph) and SI > 1.4 (right graph). (B) 
Proliferation of PBMCs to individual HLA-DR15-derived self-peptides (% of wells > SI 
2.0, n = 6) grouped by stimulatory, inhibitory and eluted peptides. (C) The most 
stimulatory peptides from B (peptide 8, 14, 20, 45, 54) were pooled and tested in a 
dose titration experiment. % wells with SI > 2 and SI > 1.4 are shown (n = 6). (D) 
Proliferation of isolated bulk CD4+ T cells in response to 5 HLA-derived peptides 
presented by APCs (BLS transfectants) expressing only DR2a, DR2b, or DQw6 
respectively (mean stimulatory index (SI) with SEM using 5 donors, 6 wells each). 
 
Figure 6. Reactivity to HLA-DRβ chain-derived, allele-specific self-peptides. (A) 
Comparison of 20 peptides derived from the polymorphic HLA-DR chains of 
DRB1*15:01 and DRB5*01:01 (5 donors, 8 wells each; * indicating P-value of < 
0.05). Scheme depicting origin of allele-specific peptides and shared peptide regions 
of the DRβ-derived sequence. (C) Comparison of the allele-specific-, DRβ chain-
derived peptides. Polymorphic amino acids are marked in red, the highest predicted 
binding affinity (consensus rank < 20%) to one of the alleles with green shading, and 
the peptide giving stronger responses in proliferation testing (see Fig. 6B) is indicated 
by grey shading. (D) Summary of 4 peptides that had been eluted from either DR2a 
or DR2b.  
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Suppl. Figure 1. Comparison of peripheral blood mononuclear cell proliferation 
over a 7-day time course. (A) Proliferation strength (mean cpm ± SEM) is observed 
between multiple sclerosis patients (MS, n = 40) and healthy donors (HD, n = 14) on 
day 1, 3 and 7. (B) Proliferation heterogeneity on day 7 is shown for HD (n = 14) and 
multiple sclerosis patients, which are subdivided into the different multiple sclerosis 
forms, clinically isolated syndrom (CIS), relapsing-remitting (RR-MS), relapsing-
remitting in relapse (RR-MS in R), primary-progress (PP-MS), secondary-progressive 
(SP-MS) (each n = 8) (standard deviation ± SEM).  
 
Suppl. Figure 2. Proliferation of peripheral blood mononuclear cells upon 
stimulation with HLA-DR15 haplotype-derived self-peptides. (A) Reactivity to 
individual pools of the HLA-DR15 haplotype-derived peptide library is shown as 
mean SI and % of wells SI > 2.0 (20 multiple sclerosis patients and 15 HD). Peptide 
pools that were selected for further fine specificity analysis are shown in red 













Suppl. Table 1: Multiple sclerosis (MS) patient and healthy donor (HD) 
demographics 
  n mean age ± SD mean cpm ± SEM mean SD ± SEM 
MS 69 39,83 ± 9,77 5337 ± 548 2099 ± 217 
HD 36 42,93 ± 15,72 3606 ± 503 1422 ± 180 
male 35 41,7 ± 14,0 4526 ± 751 1824 ± 269 
female 70 41,6 ± 11,2 4853 ± 482 1888 ± 197 
MS DR15- 22 36,35 ± 10,57 4482 ± 737 1437 ± 178 
MS DR15+ 47 40,53 ± 9,16 5737 ± 724 2408 ± 298 
HD DR15- 15 45,13 ± 16,96 2981 ± 722 1002 ± 203 
HD DR15+ 21 40,64 ± 15,07 4053 ± 688 1722 ± 257 
DR15- 37 41,7 ± 13,8 3874 ± 534 1261 ± 137 















Suppl. Table 2: Peptides eluted from DR2a and DR2b 
 
Eluted from: BLS-DR2a using HLA-DR2a-specific antibody (H0596) 
 













GYLPNQLFRTF 1653 DDX1    36 2 1355,71 -0,23
WISKQEYDESGPSIVHRKCF 60 ACTB yes 21 4 2409,16 -0,51
IIDPGDSDIIRSmPEQTGEK 6156 RPL30   21 3 2217,07 0,33
AIIDPGDSDIIRSmPEQTGEK 6156 RPL30    20 3 2288,11 0,13
VTYVPVTTFKNLQTVNVDEN 6160 RPL31    47 2 2281,18 2,27
QVTQPTVGmNFKTPRGPV 6218 RPS17    40 3 1973,03 -0,42
EVSVNQSLLQPLNVKVD 738196 KRT2    60 2 1882,03 0,86
m = oxidized Methionin        
 
Eluted from: BLS-DR2a using panHLA-class II specific antibody (L243) 
   
































yes 45 2 1969,01 1,76
 44
DGKDYIALNEDLRSW 3107 HLA-C yes 39 3 1794,86 -0,46










yes 34 3 1676,83 2,02
TQSYSLQLSNLKMED 114836 SLAMF6   65 2 1756,84 0,95
TQSYSLQLSNLKMEDT 114836 SLAMF6   42 2 1857,89 0,60
FTQSYSLQLSNLKMEDTG 114836 SLAMF6   41 2 2061,98 0,81
IHSLPPEGKLGIMEL 1351 COX8A   23 3 1633,90 -0,48
GIPEEELLRQQQELFAK 1810 DR1   22 3 2028,08 2,81
LPVPAFNVINGGSHAG 2023 ENO1 yes 78 2 1549,81 0,13
FELFPSLSHNLLVD 23549 DNPEP   20 2 1630,85 0,44
DAPMFVMGVNHEKYDN 2597 GAPDH   38 2 1866,82 0,70
DAPmFVMGVNHEKYDN 2597 GAPDH   56 2 1882,81 2,23
DAPMFVMGVNHEKYDNSL 2597 GAPDH   36 2 2066,93 1,57
ISWYDNEFGYSNRVVDL 2597 GAPDH   40 2 2076,97 1,48
DAPMFVMGVNHEKYDNSLK 2597 GAPDH   33 3 2195,03 -0,03
FPTIYFSPANKKLN 2923 PDIA3   23 3 1639,88 -0,67
GFPTIYFSPANKKLNPK 2923 PDIA3   28 3 1922,06 3,23
FPTIYFSPANKKLNPK 2923 PDIA3   31 2 1865,04 2,42
ATRLKGIVPLAKVD 2923 PDIA3   30 3 1480,92 -1,39
AHSEFLKAASNLRDNYR 2923 PDIA3   39 4 1992,00 -0,86
INKYVTILHLPKKGDD 3001 GZMA    26 4 1854,05 -0,70
GPPVSELITKAVAASKERSG 3008 HIST1H1E   30 4 1997,10 -1,66
YDMNAANVGWNNSTFA 4282 MIF   52 2 1774,75 1,12
YDmNAANVGWNNSTFA 4282 MIF   46 2 1790,75 1,09
 45
IVNTNVPRASVPDGFLSEL 4282 MIF   39 2 2028,08 1,43
DVSPSDPKIQEVYIP 5337 PLD1   25 2 1686,86 1,16
SYLDPPDLPSNSNDDLLSL 57178 ZMIZ1   20 2 2074,99 2,18
LSYLDPPDLPSNSNDDLLSL 57178 ZMIZ1   40 2 2188,07 2,03
VDIFQVVKALRKA 5788 PTPRC   32 3 1486,91 -1,11
VVDIFQVVKALRKARPG 5788 PTPRC   21 3 1896,15 -0,22
QVTQPTVGMNFKTPRGPV 6218 RPS17    46 3 1957,03 0,85
YVQSmDVAAFNKI 644820 EEF1B4  yes 34 2 1501,74 0,27
FEDYVQSMDVAAFNKI 1933 EEF1B2  yes 66 2 1876,88 1,39
PAEDWAGLDEDEDAHVWEDN 7979 SHFM1   68 2 2312,93 3,11
WQVKSGTIFDNF 811 CALR   44 2 1441,71 0,34
MIDVTKSYYQKFLPLTQV 84516 DCTN5   23 3 2174,16 -0,29
TPVYLGATAGMRLL 953 ENTPD1   78 2 1462,81 1,03
LMQALPMGALPQ 972 CD74   30 2 1269,67 0,02
KPPKPVSKmRMATPLLMQA 972 CD74 yes 27 3 2140,18 -0,57
TPLLmQALPMGALP 972 CD74 yes 22 2 1468,79 0,26
ATPLLMQALPMGALP 972 CD74 yes 22 2 1523,83 -0,45
ATPLLmQALPMGALP 972 CD74 yes 28 2 1539,83 -1,42
ATPLLMQALPmGALP 972 CD74 yes 29 2 1539,83 0,87
TPLLMQALPmGALPQ 972 CD74 yes 40 2 1596,85 1,86
TPLLmQALPmGALPQ 972 CD74 yes 23 2 1612,85 1,13
LPKPPKPVSKMRMATPLLMQAL 972 CD74 yes 24 3 2447,41 0,70
ATPLLMQALPMGALPQ 972 CD74 yes 33 2 1651,89 1,22
MATPLLMQALPMGALP 972 CD74 yes 43 2 1654,88 1,52
ATPLLMQALPmGALPQ 972 CD74 yes 28 2 1667,89 1,11
mATPLLMQALPMGALP 972 CD74 yes 61 2 1670,87 0,53
MATPLLMQALPmGALP 972 CD74 yes 35 2 1670,87 0,53
 46
MATPLLmQALPMGALP 972 CD74 yes 38 2 1670,87 0,90
mATPLLmQALPMGALP 972 CD74 yes 41 2 1686,86 -0,30
mATPLLMQALPmGALP 972 CD74 yes 50 2 1686,86 0,72
mATPLLMQALPMGALPQ 972 CD74 yes 54 2 1798,93 1,23
ATPLLMQALPMGALPQGP 972 CD74 yes 41 2 1805,97 1,98
mATPLLmQALPMGALPQ 972 CD74 yes 51 2 1814,92 1,68
MATPLLmQALPmGALPQ 972 CD74 yes 47 2 1814,92 1,68
mATPLLmQALPmGALPQ 972 CD74 yes 49 2 1830,92 1,38
ATPLLmQALPmGALPQGP 972 CD74 yes 36 2 1837,96 0,77
KPPKPVSKMRMATPLLMQA 972 CD74 yes 45 2 2124,19 1,40




  45 3 1943,08 -1,30
 
Eluted from: BLS-DR2b using HLA-DR2b-specific antibody (H0427A) 
   













DVELDDLGKDEL 10130 PDIA6   40 2 1360,65 1,23
IDLSDVELDDLGKDEL 10130 PDIA6    71 2 1788,88 1,92
IGLAKDDQLKVHGF 10209 EIF1   42 3 1540,85 -1,10
VEIGLAKDDQLKVHGF 10209 EIF1   31 3 1768,95 -2,44
AAmLDTVVFK 10213 PSMD14   46 2 1110,59 -0,95
LGISNLSQVRASN 10592 SMC2   31 2 1358,74 -0,10
FYVGEIIGKRGIIGYDV 10632 ATP5L    27 3 1899,04 -1,27
FGSAFATPFLVVRHQLLKT 1350 COX7C   43 2 2132,20 1,09
ATPFLVVRHQLLKT 1350 COX7C   27 2 1622,97 0,06
 47
FGSAFATPFLVVRHQLLKT 1350 COX7C    21 4 2132,20 0,32
YFGSAFATPFLVVRHQLLKT 1350 COX7C    26 3 2295,27 0,88
IHSLPPEGKLGImEL 1351 COX8A   48 3 1649,89 0,57
IHSLPPEGKLGIMEL 1351 COX8A   27 3 1633,90 -0,71
IHSLPPEGKLGImEL 1351 COX8A    32 3 1649,89 -1,09
AVmGFSGFGSTKKSY 153527 ZMAT2    21 3 1582,76 -0,49
GYLPNQLFRTF 1653 DDX1   37 2 1355,71 -0,65
LHLGYLPNQLFRTF 1653 DDX1   35 2 1718,94 0,38
LHLGYLPNQL 1653 DDX1   31 2 1167,65 -0,87
FSNKITPIQSKEAY 205 AK4  yes 25 3 1625,85 -0,96
PSLSHNLLVD 23549 DNPEP   29 2 1094,58 -0,17
ISWYDNEFGYSNRVVDL 2597 GAPDH   42 2 2076,97 1,25
VGAHAGEYGAEALERm 3039 HBA1   34 3 1676,77 -0,97
GKVGAHAGEYGAEALERm 3039 HBA1 yes 29 3 1861,88 -1,82
FRDGDILGKYVD 3336 HSPE1   29 2 1397,71 0,41
IVNTNVPRASVPDGFLSEL 4282 MIF   45 2 2028,08 0,59
NAANVGWNNSTFA 4282 MIF   45 2 1365,62 -0,13
mVGPIEEAVAKADKLAEEHSS 506 ATP5B    26 4 2227,09 0,32
VPPVQVSPLIKLGRYSAL 521 ATP5I   42 3 1937,16 -1,56
KFEDPKFEVIEKPQA 522 ATP5J   43 3 1804,95 0,08
PTFKFEDPKFEVIEKPQA 522 ATP5J   21 4 2150,12 -0,71
DIAVDGEPLGRVSFEL 5478 PPIA    66 2 1716,88 0,51
FVILRKNPNYDL 5708 PSMD2   24 2 1491,83 0,54
LVSNLNPERVTPQSLFIL 5725 PTBP1   21 2 2040,15 -0,14
ISKQEYDESGPSIVHRKCF 60 ACTB yes 67 2 2223,08 -1,67
WISKQEYDESGPSIVHRKCF 60 ACTB yes 67 2 2409,17 1,58
AIIDPGDSDIIRSmPEQTGEK 6156 RPL30   45 3 2288,11 0,05
 48
IIDPGDSDIIRSMPEQTGEK 6156 RPL30   27 3 2201,08 0,38
YVPVTTFKNLQTVNVDEN 6160 RPL31   56 2 2081,06 0,68
VTYVPVTTFKNLQTVNVDEN 6160 RPL31   42 2 2281,18 2,38
mRYVASYLLAALGGN 6181 RPLP2    26 2 1614,83 1,63
FSLPIKESEIIDF 6187 RPS2 yes 38 2 1537,82 0,34
QVTQPTVGMNFKTPRGPV 6218 RPS17   67 2 1957,03 1,01
YIRGVEEEEEDGEmRE 6636 SNRPF    37 3 1985,84 0,37
GDVKPVVSSTPLVDFL 6881 TAF10   37 2 1672,92 1,31
FYGQTLGQAQAHSQEQ 8939 FUBP3   37 2 1792,83 1,32
IRPEIHENYRING 9550 ATP6V1G1   22 3 1610,84 -0,38
FVCDIRPEIHENYRING 9550 ATP6V1G1    33 3 2075,01 -1,39
 
Eluted from: BLS-DR2b using panHLA-class II-specific antibody (L243) 
  













LEEFGRFASF 3122 HLA-DRA   49 2 1202,58 0,06
LEEFGRFASFEAQGA 3122 HLA-DRA   46 2 1658,78 0,47
LEEFGRFASFEAQGAL 3122 HLA-DRA   40 2 1771,86 -0,23
FGRFASFEAQG 3122 HLA-DRA   33 2 1216,57 -1,09
FGRFASFEAQGAL 3122 HLA-DRA   47 2 1400,69 -0,84
LEEFGRFASFEAQG 3122 HLA-DRA   44 2 1587,75 1,88
ATPFLVVRHQLLKT 1350 COX7C   22 3 1622,97 -0,78
IHSLPPEGKLGIMEL 1351 COX8A    20 3 1633,89 -2,22
GYLPNQLFRTF 1653 DDX1   46 2 1355,71 -0,41
QADLSSFKSQELNER 2208 FCER2   87 2 1751,86 1,22
LQADLSSFKSQELNERN 2208 FCER2   55 3 1978,98 -0,25
 49
QADLSSFKSQELNERN 2208 FCER2    34 3 1865,90 -1,85
QADLSSFKSQELNER 2208 FCER2    29 3 1751,86 0,06
LSSFKSQELNER 2208 FCER2    26 3 1437,73 -0,03
ATRLKGIVPLAKVD 2923 PDIA3   32 3 1480,92 -0,83
GFPTIYFSPANKKLNPK 2923 PDIA3    27 3 1922,05 -0,77
SLDDLQPWHSFGADS 351 APP   47 2 1674,74 1,04
LDDLQPWHSFGADS 351 APP   45 2 1587,71 0,75
SLDDLQPWHSFGADSVPA 351 APP   32 2 1941,90 1,44
DVSPSDPKIQEVYIP 5337 PLD1   26 2 1686,86 2,07
AIIDPGDSDIIRSMPEQTGEK 6156 RPL30   25 3 2272,11 0,17
VTYVPVTTFKNLQTVNVDEN 6160 RPL31   47 2 2281,18 1,95
QVTQPTVGMNFKTPRGPV 6218 RPS17   51 3 1957,03 -0,93
YVQSMDVAAFNKI 644820 EEF1B4   75 2 1485,74 0,52
WISKQEYDESGPSIVHRKCF 71 ACTG1 yes 49 3 2409,17 0,91
ISKQEYDESGPSIVHRKCF 71 ACTG1 yes 41 3 2223,09 -0,23
QQMWISKQEYDESGPSIVHRKCF 71 ACTG1 yes 22 4 2796,32 -1,03
WQVKSGTIFDNF 811 CALR   31 2 1441,71 -0,25
KPPKPVSKmRMATPLLMQA 972 CD74 yes 28 3 2140,18 0,17
MATPLLMQALPMGALP 972 CD74 yes 26 2 1654,88 1,59
ATPLLMQALPMGALPQGP 972 CD74 yes 23 2 1805,97 0,43
KPPKPVSKMRmATPLLMQA 972 CD74 yes 22 3 2140,18 0,00
KPPKPVSKMRMATPLLMQAL 972 CD74 yes 20 3 2237,27 -0,02






Suppl. Table 3: Biological pathway gene ontology annotation analysis of DR15-
eluted peptides 
 
Gene Ontology  
Biological Pathway Term 
 
 
Count PValue Gene ID (Gene) 
antigen processing and 
presentation                   
6 1,2E+11 811     (CALR)    
3135   (HLA-G)      
972     (CD74) 
3127   (HLA-DRB) 
3107   (HLA-C)   
3122   (HLA-DRA) 
generation of precursor 
metabolites and energy       
8 1,2E+11 522     (ATP5J)   
521     (ATP5I)    
1350   (COX7C) 
10632 (ATP5L) 
506     (ATP5B)   
1351   (COX8A)  
2597   (GAPDH) 
2023   (ENO1) 
translational elongation                  6 3,1E+10 6181   (RPLP2)  
6160   (RPL31)   
6187   (RPS2) 
1933   (EEF1B2) 
6218   (RPS17)   
6156   (RPL30) 
regulation of cellular protein 
metabolic process 
7 0,00699 811     (CALR)    
5708   (PSMD2) 
10213 (PSMD14) 
351     (APP) 
1653   (DDX1)  
10209 (EIF1)      
5788   (PTPRC) 
immune response 8 0,01157 4282   (MIF)       
3135   (HLA-G)   
3107   (HLA-C)   
5788   (PTPRC) 
3127   (HLA-DRB) 
3001   (GZMA)      
972     (CD74)     
3122   (HLA-DRA) 
cellular homeostasis 6 0,02609 811     (CALR)   
10130 (PDIA6)   
5788   (PTPRC) 
506     (ATP5B)   
2923   (PDIA4)      




7 0,03201 4282   (MIF)       
1653   (DDX1)       
972     (CD74)     
3008   (HIST1H1E) 
811     (CALR)    
6636   (SNRPF)  
6881   (TAF10) 
positive regulation of  
catalytic activity 
6 0,03916 5708   (PSMD2) 
10213 (PSMD14) 
3336   (HSPE1) 
2208   (FCER2)    
972     (CD74)     
5788   (PTPRC) 
macromolecular complex subunit 
organization 
7 0,04203 4282   (MIF)       
1653   (DDX1)       
972     (CD74)    
3008   (HIST1H1E) 
811     (CALR)    
6636   (SNRPF)  
6881   (TAF10) 
cation transport 6 0,04884 522     (ATP5J)     
521     (ATP5I)  
10632 (ATP5L) 
506     (ATP5B)   
9550   (ATP6V1G1) 
















Suppl. Table 4: HLA-DR15 haplotype-derived self-peptides 
 
Pool Number Peptide Number Origin Sequence Remark 
1 1 DRB1*15:01 MVCLK LPGGS CMTAL   
1 2 DRB1*15:01 CMTAL TVTLM VLSSP   
1 3 DRB1*15:01 VLSSP LALSG DTRPR   
1 4 DRB1*15:01 DTRPR FLWQP KRECH   
1 5 DRB1*15:01 KRECH FFNGT ERVRF   
2 6 DRB1*15:01 ERVRF LDRYF YNQEE   
2 7 DRB1*15:01 YNQEE SVRFD SDVGE   
2 8 DRB1*15:01 SDVGE FRAVT ELGRP   
2 9 DRβ ELGRP DAEYW NSQKD shared 
2 10 DRB1*15:01 NSQKD ILEQA RAAVD   
3 11 DRB1*15:01 RAAVD TYCRH NYGVV   
3 12 DRB1*15:01 NYGVV ESFTV QRRVQ   
3 13 DRB1*15:01 QRRVQ PKVTV YPSKT   
3 14 DRB1*15:01 YPSKT QPLQH HNLLV   
3 15 DRB1*15:01 HNLLV CSVSG FYPGS   
4 16 DRB1*15:01 FYPGS IEVRW FLNGQ   
4 17 DRB1*15:01 FLNGQ EEKAG MVSTG   
4 18 DRB1*15:01 MVSTG LIQNG DWTFQ   
4 19 DRβ DWTFQ TLVML ETVPR shared 
4 20 DRβ ETVPR SGEVY TCQVE shared 
5 21 DRβ TCQVE HPSVT SPLTV shared 
5 22 DRB1*15:01 SPLTV EWRAR SESAQ   
5 23 DRβ SESAQ SKMLS GVGGF shared 
5 24 DRβ GVGGF VLGLL FLGAG shared 
 53
5 25 DRB1*15:01 FLGAG LFIYF RNQKG   
5 26 DRB1*15:01 RNQKG HSGLQ PTGFLS   
6 27 DRB5*01:01 MVCLK LPGGS YMAKL   
6 28 DRB5*01:01 YMAKL TVTLM VLSSP   
6 29 DRB5*01:01 VLSSP LALAG DTRPR   
6 30 DRB5*01:01 DTRPR FLQQD KYECH   
6 31 DRB5*01:01 KYECH FFNGT ERVRF   
7 32 DRB5*01:01 ERVRF LHRDI YNQEE   
7 33 DRB5*01:01 YNQEE DLRFD SDVGE   
7 34 DRB5*01:01 SDVGE YRAVT ELGRP   
7 35 DRB5*01:01 NSQKD FLEDR RAAVD   
7 36 DRB5*01:01 RAAVD TYCRH NYGVG   
8 37 DRB5*01:01 NYGVG ESFTV QRRVE   
8 38 DRB5*01:01 QRRVE PKVTV YPART   
8 39 DRB5*01:01 YPART QTLQH HNLLV   
8 40 DRB5*01:01 HNLLV CSVNG FYPGS   
8 41 DRB5*01:01 FYPGS IEVRW FRNSQ   
9 42 DRB5*01:01 FRNSQ EEKAG VVSTG   
9 43 DRB5*01:01 VVSTG LIQNG DWTFQ   
9 44 DRB5*01:01 SPLTV EWRAQ SESAQ   
9 45 DRB5*01:01 FLGAG LFIYF KNQKG   
9 46 DRB5*01:01 KNQKG HSGLH PTGLVS   
10 47 DRA*01:01 MAISG VPVLG FFIIA   
10 48 DRA*01:01 FFIIA VLMSA QESWA   
10 49 DRA*01:01 QESWA IKEEH VIIQA   
10 50 DRA*01:01 VIIQA EFYLN PDQSG   
10 51 DRA*01:01 PDQSG EFMFD FDGDE   
 54
11 52 DRA*01:01 FDGDE IFHVD MAKKE   
11 53 DRA*01:01 MAKKE TVWRL EEFGR   
11 54 DRA*01:01 EEFGR FASFE AQGAL   
11 55 DRA*01:01 AQGAL ANIAV DKANL   
11 56 DRA*01:01 DKANL EIMTK RSNYT   
12 57 DRA*01:01 RSNYT PITNV PPEVT   
12 58 DRA*01:01 PPEVT VLTNS PVELR   
12 59 DRA*01:01 PVELR EPNVL ICFID   
12 60 DRA*01:01 ICFID KFTPP VVNVT   
12 61 DRA*01:01 VVNVT WLRNG KPVTT   
13 62 DRA*01:01 KPVTT GVSET VFLPR   
13 63 DRA*01:01 VFLPR EDHLF RKFHY   
13 64 DRA*01:01 RKFHY LPFLP STEDV   
13 65 DRA*01:01 STEDV YDCRV EHWGL   
13 66 DRA*01:01 EHWGL DEPLL KHWEF   
14 67 DRA*01:01 KHWEF DAPSP LPETT   
14 68 DRA*01:01 LPETT ENVVC ALGLT   
14 69 DRA*01:01 ALGLT VGLVG IIIGT   
14 70 DRA*01:01 IIIGT IFIIK GVRKS   
14 71 DRA*01:01 GVRKS NAAER RGPL   
15 72 DQA1*01:02 MILNK ALLLG ALALT   
15 73 DQA1*01:02 ALALT TVMSP CGGED   
15 74 DQA1*01:02 CGGED IVADH VASCG   
15 75 DQA1*01:02 VASCG VNLYQ FYGPS   
15 76 DQA1*01:02 FYGPS GQYTH EFDGD   
16 77 DQA1*01:02 EFDGD EQFYV DLERK   
16 78 DQA1*01:02 DLERK ETAWR WPEFS   
 55
16 79 DQA1*01:02 WPEFS KFGGF DPQGA   
16 80 DQA1*01:02 DPQGA LRNMA VAKHN   
16 81 DQA1*01:02 VAKHN LNIMI KRYNS   
17 82 DQA1*01:02 KRYNS TAATN EVPEV   
17 83 DQA1*01:02 EVPEV TVFSK SPVTL   
17 84 DQA1*01:02 SPVTL GQPNT LICLV   
17 85 DQA1*01:02 LICLV DNIFP PVVNI   
17 86 DQA1*01:02 PVVNI TWLSN GQSVT   
18 87 DQA1*01:02 GQSVT EGVSE TSFLS   
18 88 DQA1*01:02 TSFLS KSDHS FFKIS   
18 89 DQA1*01:02 FFKIS YLTFL PSADE   
18 90 DQA1*01:02 PSADE IYDCK VEHWG   
18 91 DQA1*01:02 VEHWG LDQPL LKHWE   
19 92 DQA1*01:02 LKHWE PEIPA PMSEL   
19 93 DQA1*01:02 PMSEL TETVV CALGL   
19 94 DQA1*01:02 CALGL SVGLM GIVVG   
19 95 DQA1*01:02 GIVVG TVFII QGLRS   
19 96 DQA1*01:02 QGLRS VGASR HQGPL   
20 97 DQB1*06:02 MSWKK ALRIP GDLRV   
20 98 DQB1*06:02 GDLRV ATVTL MLAML   
20 99 DQB1*06:02 MLAML SSLLA EGRDS   
20 100 DQB1*06:02 EGRDS PEDFV FQFKG   
20 101 DQB1*06:02 FQFKG MCYFT NGTER   
21 102 DQB1*06:02 NGTER VRLVT RYIYN   
21 103 DQB1*06:02 RYIYN REEYA RFDSD   
21 104 DQB1*06:02 RFDSD VGVYR AVTPQ   
21 105 DQB1*06:02 AVTPQ GRPDA EYWNS   
 56
21 106 DQB1*06:02 EYWNS QKEVL EGTRA   
22 107 DQB1*06:02 EGTRA ELDTV CRHNY   
22 108 DQB1*06:02 CRHNY EVAFR GILQR   
22 109 DQB1*06:02 GILQR RVEPT VTISP   
22 110 DQB1*06:02 VTISP SRTEA LNHHN   
22 111 DQB1*06:02 LNHHN LLVCS VTDFY   
23 112 DQB1*06:02 VTDFY PGQIK VRWFR   
23 113 DQB1*06:02 VRWFR NDQEE TAGVV   
23 114 DQB1*06:02 TAGVV STPLI RNGDW   
23 115 DQB1*06:02 RNGDW TFQIL VMLEM   
23 116 DQB1*06:02 VMLEM TPQRG DVYTC   
24 117 DQB1*06:02 DVYTC HVEHP SLQSP   
24 118 DQB1*06:02 SLQSP ITVEW RAQSE   
24 119 DQB1*06:02 RAQSE SAQSK MLSGV   
24 120 DQB1*06:02 MLSGV GGFVL GLIFL   
24 121 DQB1*06:02 GLIFL GLGLI IRQRS   
24 122 DQB1*06:02 IRQRS QKGLL H   
 
 
 
 
